Comparative Pharmacology
Head-to-head clinical analysis: TOLECTIN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOLECTIN versus TOLECTIN DS.
TOLECTIN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
400-600 mg orally three times daily; maximum 1.8 g/day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category C
Category C
NSAID
NSAID